The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy
Abstract
The introduction of immunotherapy and its ultimate success will require re-evaluation of the pathogenesis of Alzheimer's disease particularly with regard to the role of the ageing microvasculature and the effects of APOE genotype. Arteries in the brain have two major functions (a) delivery of blood and (b) elimination of interstitial fluid and solutes, including amyloid-beta (Abeta), along perivascular pathways (lymphatic drainage). Both these functions fail with age and particularly severely in Alzheimer's disease and vascular dementia. Accumulation of Abeta as plaques in brain parenchyma and artery walls as cerebral amyloid angiopathy (CAA) is associated with failure of perivascular elimination of Abeta from the brain in the elderly and in Alzheimer's disease. High levels of soluble Abeta in the brain correlate with cognitive decline in Alzheimer's disease and reflect the failure of perivascular drainage of solutes from the brain and loss of homeostasis of the neuronal environment. Clinically and pathologically, there is a spectrum of disease related to functional failure of the ageing microvasculature with "pure" Alzheimer's disease at one end of the spectrum and vascular dementia at the other end. Changes in the cerebral microvasculature with age have a potential impact on therapy with cholinesterase inhibitors and especially on immunotherapy that removes Abeta from plaques in the brain, but results in an increase in severity of CAA and no clear improvement in cognition. Drainage of Abeta along perivascular pathways in ageing artery walls may need to be improved to maximise the potential for improvement of cognitive function with immunotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in Alzheimer disease and CAA, accumulation of Aβ in the media of cortical arterioles weakens the vessel wall and increases the chance of lobar hemorrhages.109”
In the citing paper
“CAA is a major cause of SMC vascular degeneration that is associated with BBB breakdown at the arterial and/or arteriolar level, lobar microbleeds, infarcts, white matter changes, and cognitive impairment worsening AD pathology (514, 640).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [640]
In the citing paper
“Such white matter alterations cannot be fully accounted for as degenerative processes secondary to grey matter damage (Brun and Englund, 1986; Englund, 1998; Agosta et al., 2011), but may stem from vascular amyloid deposition and microvascular damage (Weller et al., 2009).”
From White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease (2018) · cites this paper as Weller et al., 2009
In the citing paper
“CAA is caused by A 𝛃 deposition in the vascular wall of small brain arteries and capillaries and develops as a result of an imbalance between A 𝛃 production and clearance, particularly faulty transvascular and perivascular clearance of A 𝛃 from the brain (318, 420, 581, 640).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [640]
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063 · cited 1×
“A is derived from the enzymic cleavage of the transmembrane amyloid precursor protein (APP) [76, 77] resulting in a small pool of soluble A in normal brain [43].”
BackgroundImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530 · cited 2×
“brain and eventually the rise in levels of soluble A in Alzheimer’s disease [49, 51] reXect the failure of mechanisms by which A is normally eliminated from the brain [92].”
BackgroundHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Self-citationShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
(1964) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1964.tb115841.x · Cited by 1,409
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“Subsequent studies have conWrmed that clearance of A plaques can occur as a result of immunotherapy in humans with Alzheimer’s disease (Elan Pharmaceuticals AN1792) [16, 30, 37, 50, 56, 57], although there is little evidence yet that this beneWts cognitive function [37].”
BackgroundSelf-citationSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“cern in the human clinical trials [59].”
(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Research works printed but not linked: 1
- Poirier J, Derouesne C (1985) Le concept de lacune cerebrale de 1838 a nos jours. Rev Neurol 141:3–17
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
The Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Glymphatic MRI in idiopathic normal pressure hydrocephalus
Ringstad, G., Vatnehol, S. A. S., & Eide, P. K. (2017) · Brain · doi:10.1093/brain/awx191 · Cited by 722
“Presence of soluble amyloid-b deposits in the walls of leptomeningeal arteries has previously led to the conclusion that CSF and solutes exit the brain along arteries (Weller et al., 2009).”
Background
Metadata
- Authors
- Weller, R. O., Boche, D., & Nicoll, J. A. R.
- Affiliations
- Southampton General Hospital (GB)
- Corresponding author
- Weller, Roy O.
- Venue
- Acta Neuropathologica
- Published
- 2009-02-22
- Volume
- 118
- Issue
- 1
- Pages
- 87-102
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2128307173
- Cited by
- 297
- References
- 101
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 14 · 2023: 9 · 2022: 16 · 2021: 11 · 2020: 20 · 2019: 13 · 2018: 23 · 2017: 15 · 2016: 16 · 2015: 23 · 2014: 27 · 2013: 24 · 2012: 17
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Funders
- University of Southampton
- Chinese Academy of Agricultural Sciences
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- Alzheimer's disease, cerebral amyloid angiopathy, cerebral microvasculature, aging, amyloid-beta, APOE genotype, immunotherapy, cholinesterase inhibitors, vascular dementia, cognitive decline, amyloid plaques
- MeSH terms
- Aging, Alzheimer Disease, Animals, Brain, Cholinesterase Inhibitors, Humans, Dementia, Vascular, Amyloid beta-Peptides, Cerebral Amyloid Angiopathy, Microvessels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. https://app.cochat.ai/papers/10.1007/s00401-009-0498-z
- The paper
- Weller, R. O., Boche, D., & Nicoll, J. A. R. (2009). Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathologica. https://doi.org/10.1007/s00401-009-0498-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.